KR101081040B1 - 비만 및/또는 당뇨를 진단, 관찰 및 치료하기 위한 조성물,시약 및 키트와 이를 위한 방법 - Google Patents

비만 및/또는 당뇨를 진단, 관찰 및 치료하기 위한 조성물,시약 및 키트와 이를 위한 방법 Download PDF

Info

Publication number
KR101081040B1
KR101081040B1 KR1020067004972A KR20067004972A KR101081040B1 KR 101081040 B1 KR101081040 B1 KR 101081040B1 KR 1020067004972 A KR1020067004972 A KR 1020067004972A KR 20067004972 A KR20067004972 A KR 20067004972A KR 101081040 B1 KR101081040 B1 KR 101081040B1
Authority
KR
South Korea
Prior art keywords
leu
gly
ala
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067004972A
Other languages
English (en)
Korean (ko)
Other versions
KR20060083208A (ko
Inventor
리아트 민쯔
Original Assignee
리아트 민쯔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리아트 민쯔 filed Critical 리아트 민쯔
Publication of KR20060083208A publication Critical patent/KR20060083208A/ko
Application granted granted Critical
Publication of KR101081040B1 publication Critical patent/KR101081040B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020067004972A 2003-09-11 2004-09-09 비만 및/또는 당뇨를 진단, 관찰 및 치료하기 위한 조성물,시약 및 키트와 이를 위한 방법 Expired - Fee Related KR101081040B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/659,782 2003-09-11
US10/659,782 US7176292B2 (en) 2003-09-11 2003-09-11 Ghrelin variant protein
PCT/US2004/029230 WO2005026392A2 (en) 2003-09-11 2004-09-09 Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes

Publications (2)

Publication Number Publication Date
KR20060083208A KR20060083208A (ko) 2006-07-20
KR101081040B1 true KR101081040B1 (ko) 2011-11-09

Family

ID=34273528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067004972A Expired - Fee Related KR101081040B1 (ko) 2003-09-11 2004-09-09 비만 및/또는 당뇨를 진단, 관찰 및 치료하기 위한 조성물,시약 및 키트와 이를 위한 방법

Country Status (14)

Country Link
US (2) US7176292B2 (https=)
EP (1) EP1664346B1 (https=)
JP (2) JP2007504825A (https=)
KR (1) KR101081040B1 (https=)
CN (1) CN101023184A (https=)
AT (1) ATE480641T1 (https=)
AU (2) AU2004273053B2 (https=)
BR (1) BRPI0414365A (https=)
CA (1) CA2538514C (https=)
DE (1) DE602004029061D1 (https=)
IL (2) IL174195A (https=)
NZ (1) NZ546488A (https=)
RU (1) RU2420583C2 (https=)
WO (1) WO2005026392A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512971B2 (en) * 2002-12-10 2013-08-20 Echelon Biosciences, Inc. Compounds and methods of use thereof for assaying lysophospholipase D activity
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
EP1747264B1 (de) 2004-05-21 2012-09-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multizelluläre gewebe- und organkultursysteme
WO2005119525A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. 11βHSD1 CRYSTAL STRUCTURES FOR STRUCTURE BASED DRUG DESIGN
WO2007055996A2 (en) * 2005-11-03 2007-05-18 Liat Mintz Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
NZ571183A (en) * 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
WO2007126792A2 (en) * 2006-03-28 2007-11-08 Liat Mintz Use of ghrelin splice variant for treating high cholesterol levels or high plasma glucose levels and releated diseases
WO2009048903A1 (en) * 2007-10-08 2009-04-16 Bristol-Myers Squibb Company 11 beta hydroxysteroid dehydrogenase type 1
JP2011516038A (ja) * 2008-03-12 2011-05-26 オタゴ イノベーション リミテッド バイオマーカー
ES2372337B1 (es) * 2010-06-10 2013-01-18 Servicio Andaluz De Salud Variante de la ghrelina y sus usos.
WO2013113916A2 (en) * 2012-02-03 2013-08-08 Zealand Pharma A/S Ghrelin analogues
CN102721819B (zh) * 2012-06-28 2014-08-13 广州瑞博奥生物科技有限公司 一种脂联素的竞争抑制性酶联免疫检测试剂盒及方法
US20190316204A1 (en) * 2015-07-24 2019-10-17 Korea University Research And Business Foundation Biomarker for determining aging, determining obesity, and diagnosing cancer and diagnosing kit using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291653B1 (en) * 1997-03-24 2001-09-18 Zymogenetics, Inc. Antibodies to motilin homologs
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
DK1426764T3 (da) * 2001-08-17 2011-06-27 Fujirebio Kk Fremgangsmåde til diagnosticering eller monitorering af fejl i sukkermetabolisme
EP1458758A2 (en) * 2001-12-21 2004-09-22 Maxygen Aps Adiponectin fragments and conjugates
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2473781A1 (en) * 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
JPWO2003063894A1 (ja) * 2002-01-31 2005-05-26 独立行政法人科学技術振興機構 インスリン抵抗性改善剤
NZ571183A (en) * 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mol Genet Metab, Vol. 79, No. 3, pp183-188 (2003.06.11.)

Also Published As

Publication number Publication date
CN101023184A (zh) 2007-08-22
WO2005026392A2 (en) 2005-03-24
RU2006111720A (ru) 2007-10-20
US20050059015A1 (en) 2005-03-17
WO2005026392A3 (en) 2005-08-11
JP5314658B2 (ja) 2013-10-16
ATE480641T1 (de) 2010-09-15
NZ546488A (en) 2009-01-31
US20070086997A1 (en) 2007-04-19
US7176292B2 (en) 2007-02-13
JP2007504825A (ja) 2007-03-08
EP1664346B1 (en) 2010-09-08
US8088730B2 (en) 2012-01-03
IL174195A0 (en) 2006-08-01
AU2004273053A1 (en) 2005-03-24
HK1092841A1 (en) 2007-02-16
CA2538514C (en) 2014-04-08
AU2010212460A1 (en) 2010-09-09
BRPI0414365A (pt) 2006-11-14
JP2011182776A (ja) 2011-09-22
IL174195A (en) 2012-08-30
IL200120A0 (en) 2011-08-01
AU2004273053B2 (en) 2010-05-20
KR20060083208A (ko) 2006-07-20
DE602004029061D1 (de) 2010-10-21
CA2538514A1 (en) 2005-03-24
EP1664346A2 (en) 2006-06-07
RU2420583C2 (ru) 2011-06-10

Similar Documents

Publication Publication Date Title
JP5314658B2 (ja) 肥満および／または糖尿病を診断、モニタリング、および治療するための組成物、試薬、およびキット、ならびにその方法
US20020061525A1 (en) Sequences of trail variants
US20040170975A1 (en) Variant of TNF-receptor
WO2001036632A2 (en) Variants of alternative splicing
US6994994B1 (en) Splice variants of CD40-receptor
WO2002006315A2 (en) Novel nucleic acid and amino acid sequences
US6783954B2 (en) VEGF nucleic acid and amino acid sequences
HK1092841B (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes
US7858744B2 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
US20050281810A1 (en) Variants of alternative splicing
WO2000044784A1 (en) Nucleic acid and amino acid sequences
EP1417310A2 (en) Nucleic acid and amino acid sequences of a vegf variant
EP1268811A2 (en) Pi3k - regulatory subunit homologue

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140930

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161017

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20171018

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20181030

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191102

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191102

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000